FibroBiologics presents preclinical thymus organoid data targeting age-related immune decline

FibroBiologics, Inc.

FibroBiologics, Inc.

FBLG

0.00

  • FibroBiologics presented preclinical data at Keystone Symposia on Aging and Immunity for a thymus organoid platform aimed at reversing age-related immune decline.
  • Mouse studies showed transplanted organoids generated functional T cells, supporting potential to restore immune function as thymus activity wanes with age.
  • Separate cancer-model work indicated organoid-derived antigen-specific immune cells slowed tumor growth, suggesting potential oncology applications.
  • Program positioned as a scalable, injectable, cryopreservable organoid product, signaling a potential pipeline expansion beyond fibroblast-based therapeutics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604100830PRIMZONEFULLFEED9687534) on April 10, 2026, and is solely responsible for the information contained therein.